Questions?
For media relations inquiries, please contact
Media_MTPA@mt-pharma-us.com
We know that collaboration and an open exchange of ideas are important to developing effective new treatments. Our Medical Affairs team works with scientific communities in the U.S. to share knowledge and facilitate educational and research programs.
Mitsubishi Tanabe Pharma America’s acceptance of a funding request is dependent upon multiple factors including, but not limited to, scientific merit, company goals, and availability of resources/funding.
Learn MoreRegistration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
MTPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
b. Disclosure of clinical trial summary results
MTPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if MTPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.